 | • レポートコード：D0804-06508 • 出版社/出版日：GlobalInfoResearch / 2020年7月28日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、109ページ • 納品方法：Eメール • 産業分類：医薬品・治療 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、視神経脊髄炎用薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。視神経脊髄炎用薬の種類別市場規模（グルココルチコイド、免疫療法、その他）、用途別市場規模（急性発作、寛解予防的治療）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、Tianjin Kingyork、Sandoz、Fresenius、NANG KUANG、Teva、CSL、Gyjtrs、Intas、Baxter、Grifols、Octapharma、CBOP ・地域別グローバル市場分析 2015年-2020年 ・視神経脊髄炎用薬の北米市場（アメリカ、カナダ、メキシコ） ・視神経脊髄炎用薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・視神経脊髄炎用薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・視神経脊髄炎用薬の南米市場（ブラジル、アルゼンチン） ・視神経脊髄炎用薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：グルココルチコイド、免疫療法、その他 ・用途別分析：急性発作、寛解予防的治療 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The Drugs for Neuromyelitis Optica market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Drugs for Neuromyelitis Optica sales will be xx in 2020 from Drugs for Neuromyelitis Optica million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Drugs for Neuromyelitis Optica market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Drugs for Neuromyelitis Optica industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Drugs for Neuromyelitis Optica and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Drugs for Neuromyelitis Optica market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Drugs for Neuromyelitis Optica market has been segmented into
Glucocorticoids
Immunotherapies
Other
By Application, Drugs for Neuromyelitis Optica has been segmented into:
Acute Attack
Remission Prophylactic Treatment
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Drugs for Neuromyelitis Optica market presented in the report. This section sheds light on the sales growth of different regional and country-level Drugs for Neuromyelitis Optica markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Drugs for Neuromyelitis Optica market.
The report offers in-depth assessment of the growth and other aspects of the Drugs for Neuromyelitis Optica market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Drugs for Neuromyelitis Optica Market Share Analysis
Drugs for Neuromyelitis Optica competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Drugs for Neuromyelitis Optica sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Drugs for Neuromyelitis Optica sales, revenue and market share for each player covered in this report.
The major players covered in Drugs for Neuromyelitis Optica are:
Pfizer
Tianjin Kingyork
Sandoz
Fresenius
NANG KUANG
Teva
CSL
Gyjtrs
Intas
Baxter
Grifols
Octapharma
CBOP
Among other players domestic and global, Drugs for Neuromyelitis Optica market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for Neuromyelitis Optica product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Drugs for Neuromyelitis Optica, with price, sales, revenue and global market share of Drugs for Neuromyelitis Optica in 2018 and 2019.
Chapter 3, the Drugs for Neuromyelitis Optica competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for Neuromyelitis Optica breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Drugs for Neuromyelitis Optica market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Drugs for Neuromyelitis Optica sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Drugs for Neuromyelitis Optica Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Drugs for Neuromyelitis Optica Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Glucocorticoids
1.2.3 Immunotherapies
1.2.4 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Drugs for Neuromyelitis Optica Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Acute Attack
1.3.3 Remission Prophylactic Treatment
1.4 Overview of Global Drugs for Neuromyelitis Optica Market
1.4.1 Global Drugs for Neuromyelitis Optica Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
1.6 COVID-19 Outbreak: Drugs for Neuromyelitis Optica Industry Impact
1.6.1 COVID-19 Potential Implications for the Drugs for Neuromyelitis Optica
1.6.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Drugs for Neuromyelitis Optica
1.6.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.6.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.6.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.6.2 Opportunity Analysis in Covid-19 Crisis
1.6.3 Market Risk and Restraints
1.6.4 Market Driving Force
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Tianjin Kingyork
2.2.1 Tianjin Kingyork Details
2.2.2 Tianjin Kingyork Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Tianjin Kingyork SWOT Analysis
2.2.4 Tianjin Kingyork Product and Services
2.2.5 Tianjin Kingyork Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Sandoz
2.3.1 Sandoz Details
2.3.2 Sandoz Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Sandoz SWOT Analysis
2.3.4 Sandoz Product and Services
2.3.5 Sandoz Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Fresenius
2.4.1 Fresenius Details
2.4.2 Fresenius Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Fresenius SWOT Analysis
2.4.4 Fresenius Product and Services
2.4.5 Fresenius Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 NANG KUANG
2.5.1 NANG KUANG Details
2.5.2 NANG KUANG Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 NANG KUANG SWOT Analysis
2.5.4 NANG KUANG Product and Services
2.5.5 NANG KUANG Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Teva
2.6.1 Teva Details
2.6.2 Teva Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Teva Product and Services
2.6.4 Teva Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 CSL
2.7.1 CSL Details
2.7.2 CSL Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 CSL Product and Services
2.7.4 CSL Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Gyjtrs
2.8.1 Gyjtrs Details
2.8.2 Gyjtrs Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Gyjtrs Product and Services
2.8.4 Gyjtrs Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Intas
2.9.1 Intas Details
2.9.2 Intas Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Intas Product and Services
2.9.4 Intas Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Baxter
2.10.1 Baxter Details
2.10.2 Baxter Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Baxter Product and Services
2.10.4 Baxter Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Grifols
2.11.1 Grifols Details
2.11.2 Grifols Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Grifols Product and Services
2.11.4 Grifols Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 Octapharma
2.12.1 Octapharma Details
2.12.2 Octapharma Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Octapharma Product and Services
2.12.4 Octapharma Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 CBOP
2.13.1 CBOP Details
2.13.2 CBOP Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 CBOP Product and Services
2.13.4 CBOP Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Drugs for Neuromyelitis Optica Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Drugs for Neuromyelitis Optica Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Drugs for Neuromyelitis Optica Manufacturer Market Share in 2019
3.3.2 Top 6 Drugs for Neuromyelitis Optica Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Drugs for Neuromyelitis Optica Sales, Revenue and Market Share by Regions
4.1.1 Global Drugs for Neuromyelitis Optica Sales and Market Share by Regions (2015-2020)
4.1.2 Global Drugs for Neuromyelitis Optica Revenue and Market Share by Regions (2015-2020)
4.2 North America Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
4.3 Europe Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
4.5 South America Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Drugs for Neuromyelitis Optica Sales, Revenue and Market Share by Country
5.1.1 North America Drugs for Neuromyelitis Optica Sales and Market Share by Country (2015-2020)
5.1.2 North America Drugs for Neuromyelitis Optica Revenue and Market Share by Country (2015-2020)
5.2 United States Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
5.3 Canada Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
5.4 Mexico Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Drugs for Neuromyelitis Optica Sales, Revenue and Market Share by Country
6.1.1 Europe Drugs for Neuromyelitis Optica Sales and Market Share by Country (2015-2020)
6.1.2 Europe Drugs for Neuromyelitis Optica Revenue and Market Share by Country (2015-2020)
6.2 Germany Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
6.3 UK Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
6.4 France Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
6.5 Russia Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
6.6 Italy Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Drugs for Neuromyelitis Optica Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Drugs for Neuromyelitis Optica Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Drugs for Neuromyelitis Optica Revenue and Market Share by Regions (2015-2020)
7.2 China Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
7.3 Japan Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
7.4 Korea Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
7.5 India Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
7.7 Australia Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Drugs for Neuromyelitis Optica Sales, Revenue and Market Share by Country
8.1.1 South America Drugs for Neuromyelitis Optica Sales and Market Share by Country (2015-2020)
8.1.2 South America Drugs for Neuromyelitis Optica Revenue and Market Share by Country (2015-2020)
8.2 Brazil Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
8.3 Argentina Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Drugs for Neuromyelitis Optica Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Drugs for Neuromyelitis Optica Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Drugs for Neuromyelitis Optica Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
9.3 Turkey Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
9.4 Egypt Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
9.5 South Africa Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Drugs for Neuromyelitis Optica Sales and Market Share by Type (2015-2020)
10.2 Global Drugs for Neuromyelitis Optica Revenue and Market Share by Type (2015-2020)
10.3 Global Drugs for Neuromyelitis Optica Price by Type (2015-2020)
11 Global Drugs for Neuromyelitis Optica Market Segment by Application
11.1 Global Drugs for Neuromyelitis Optica Sales Market Share by Application (2015-2020)
11.2 Global Drugs for Neuromyelitis Optica Revenue Market Share by Application (2015-2020)
11.3 Global Drugs for Neuromyelitis Optica Price by Application (2015-2020)
12 Market Forecast
12.1 Global Drugs for Neuromyelitis Optica Sales, Revenue and Growth Rate (2021-2025)
12.2 Drugs for Neuromyelitis Optica Market Forecast by Regions (2021-2025)
12.2.1 North America Drugs for Neuromyelitis Optica Market Forecast (2021-2025)
12.2.2 Europe Drugs for Neuromyelitis Optica Market Forecast (2021-2025)
12.2.3 Asia-Pacific Drugs for Neuromyelitis Optica Market Forecast (2021-2025)
12.2.4 South America Drugs for Neuromyelitis Optica Market Forecast (2021-2025)
12.2.5 Middle East & Africa Drugs for Neuromyelitis Optica Market Forecast (2021-2025)
12.3 Drugs for Neuromyelitis Optica Market Forecast by Type (2021-2025)
12.3.1 Global Drugs for Neuromyelitis Optica Sales Forecast by Type (2021-2025)
12.3.2 Global Drugs for Neuromyelitis Optica Market Share Forecast by Type (2021-2025)
12.4 Drugs for Neuromyelitis Optica Market Forecast by Application (2021-2025)
12.4.1 Global Drugs for Neuromyelitis Optica Sales Forecast by Application (2021-2025)
12.4.2 Global Drugs for Neuromyelitis Optica Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Drugs for Neuromyelitis Optica Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Drugs for Neuromyelitis Optica by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Drugs for Neuromyelitis Optica Market Size and Growth Estimation in Various Scenarios in 2020
Table 4. Global Drugs for Neuromyelitis Optica Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 5. Market Opportunities in Next Few Years
Table 6. Market Risks Analysis
Table 7. Market Drivers
Table 8. Pfizer Basic Information, Manufacturing Base and Competitors
Table 9. Pfizer Drugs for Neuromyelitis Optica Major Business
Table 10. Pfizer Drugs for Neuromyelitis Optica Total Revenue (USD Million) (2018-2019)
Table 11. Pfizer SWOT Analysis
Table 12. Pfizer Drugs for Neuromyelitis Optica Product and Services
Table 13. Pfizer Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 14. Tianjin Kingyork Basic Information, Manufacturing Base and Competitors
Table 15. Tianjin Kingyork Drugs for Neuromyelitis Optica Major Business
Table 16. Tianjin Kingyork Drugs for Neuromyelitis Optica Total Revenue (USD Million) (2018-2019)
Table 17. Tianjin Kingyork SWOT Analysis
Table 18. Tianjin Kingyork Drugs for Neuromyelitis Optica Product and Services
Table 19. Tianjin Kingyork Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 20. Sandoz Basic Information, Manufacturing Base and Competitors
Table 21. Sandoz Drugs for Neuromyelitis Optica Major Business
Table 22. Sandoz Drugs for Neuromyelitis Optica Total Revenue (USD Million) (2018-2019)
Table 23. Sandoz SWOT Analysis
Table 24. Sandoz Drugs for Neuromyelitis Optica Product and Services
Table 25. Sandoz Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 26. Fresenius Basic Information, Manufacturing Base and Competitors
Table 27. Fresenius Drugs for Neuromyelitis Optica Major Business
Table 28. Fresenius Drugs for Neuromyelitis Optica Total Revenue (USD Million) (2018-2019)
Table 29. Fresenius SWOT Analysis
Table 30. Fresenius Drugs for Neuromyelitis Optica Product and Services
Table 31. Fresenius Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 32. NANG KUANG Basic Information, Manufacturing Base and Competitors
Table 33. NANG KUANG Drugs for Neuromyelitis Optica Major Business
Table 34. NANG KUANG Drugs for Neuromyelitis Optica Total Revenue (USD Million) (2018-2019)
Table 35. NANG KUANG SWOT Analysis
Table 36. NANG KUANG Drugs for Neuromyelitis Optica Product and Services
Table 37. NANG KUANG Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 38. Teva Basic Information, Manufacturing Base and Competitors
Table 39. Teva Drugs for Neuromyelitis Optica Major Business
Table 40. Teva Drugs for Neuromyelitis Optica Total Revenue (USD Million) (2018-2019)
Table 41. Teva SWOT Analysis
Table 42. Teva Drugs for Neuromyelitis Optica Product and Services
Table 43. Teva Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 44. CSL Basic Information, Manufacturing Base and Competitors
Table 45. CSL Drugs for Neuromyelitis Optica Major Business
Table 46. CSL Drugs for Neuromyelitis Optica Total Revenue (USD Million) (2018-2019)
Table 47. CSL SWOT Analysis
Table 48. CSL Drugs for Neuromyelitis Optica Product and Services
Table 49. CSL Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 50. Gyjtrs Basic Information, Manufacturing Base and Competitors
Table 51. Gyjtrs Drugs for Neuromyelitis Optica Major Business
Table 52. Gyjtrs Drugs for Neuromyelitis Optica Total Revenue (USD Million) (2018-2019)
Table 53. Gyjtrs SWOT Analysis
Table 54. Gyjtrs Drugs for Neuromyelitis Optica Product and Services
Table 55. Gyjtrs Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 56. Intas Basic Information, Manufacturing Base and Competitors
Table 57. Intas Drugs for Neuromyelitis Optica Major Business
Table 58. Intas Drugs for Neuromyelitis Optica Total Revenue (USD Million) (2018-2019)
Table 59. Intas SWOT Analysis
Table 60. Intas Drugs for Neuromyelitis Optica Product and Services
Table 61. Intas Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 62. Baxter Basic Information, Manufacturing Base and Competitors
Table 63. Baxter Drugs for Neuromyelitis Optica Major Business
Table 64. Baxter Drugs for Neuromyelitis Optica Total Revenue (USD Million) (2018-2019)
Table 65. Baxter SWOT Analysis
Table 66. Baxter Drugs for Neuromyelitis Optica Product and Services
Table 67. Baxter Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 68. Grifols Basic Information, Manufacturing Base and Competitors
Table 69. Grifols Drugs for Neuromyelitis Optica Major Business
Table 70. Grifols Drugs for Neuromyelitis Optica Total Revenue (USD Million) (2018-2019)
Table 71. Grifols SWOT Analysis
Table 72. Grifols Drugs for Neuromyelitis Optica Product and Services
Table 73. Grifols Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 74. Octapharma Basic Information, Manufacturing Base and Competitors
Table 75. Octapharma Drugs for Neuromyelitis Optica Major Business
Table 76. Octapharma Drugs for Neuromyelitis Optica Total Revenue (USD Million) (2018-2019)
Table 77. Octapharma SWOT Analysis
Table 78. Octapharma Drugs for Neuromyelitis Optica Product and Services
Table 79. Octapharma Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 80. CBOP Basic Information, Manufacturing Base and Competitors
Table 81. CBOP Drugs for Neuromyelitis Optica Major Business
Table 82. CBOP Drugs for Neuromyelitis Optica Total Revenue (USD Million) (2018-2019)
Table 83. CBOP SWOT Analysis
Table 84. CBOP Drugs for Neuromyelitis Optica Product and Services
Table 85. CBOP Drugs for Neuromyelitis Optica Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 86. Global Drugs for Neuromyelitis Optica Sales by Manufacturer (2018-2019) (K Units)
Table 87. Global Drugs for Neuromyelitis Optica Revenue by Manufacturer (2018-2019) (USD Million)
Table 88. Global Drugs for Neuromyelitis Optica Sales by Regions (2015-2020) (K Units)
Table 89. Global Drugs for Neuromyelitis Optica Sales Market Share by Regions (2015-2020)
Table 90. Global Drugs for Neuromyelitis Optica Revenue by Regions (2015-2020) (USD Million)
Table 91. North America Drugs for Neuromyelitis Optica Sales by Countries (2015-2020) (K Units)
Table 92. North America Drugs for Neuromyelitis Optica Sales Market Share by Countries (2015-2020)
Table 93. North America Drugs for Neuromyelitis Optica Revenue by Countries (2015-2020) (USD Million)
Table 94. North America Drugs for Neuromyelitis Optica Revenue Market Share by Countries (2015-2020)
Table 95. Europe Drugs for Neuromyelitis Optica Sales by Countries (2015-2020) (K Units)
Table 96. Europe Drugs for Neuromyelitis Optica Sales Market Share by Countries (2015-2020)
Table 97. Europe Drugs for Neuromyelitis Optica Revenue by Countries (2015-2020) (USD Million)
Table 98. Asia-Pacific Drugs for Neuromyelitis Optica Sales by Regions (2015-2020) (K Units)
Table 99. Asia-Pacific Drugs for Neuromyelitis Optica Sales Market Share by Regions (2015-2020)
Table 100. Asia-Pacific Drugs for Neuromyelitis Optica Revenue by Regions (2015-2020) (USD Million)
Table 101. South America Drugs for Neuromyelitis Optica Sales by Countries (2015-2020) (K Units)
Table 102. South America Drugs for Neuromyelitis Optica Sales Market Share by Countries (2015-2020)
Table 103. South America Drugs for Neuromyelitis Optica Revenue by Countries (2015-2020) (USD Million)
Table 104. South America Drugs for Neuromyelitis Optica Revenue Market Share by Countries (2015-2020)
Table 105. Middle East & Africa Drugs for Neuromyelitis Optica Sales by Countries (2015-2020) (K Units)
Table 106. Middle East & Africa Drugs for Neuromyelitis Optica Sales Market Share by Countries (2015-2020)
Table 107. Middle East & Africa Drugs for Neuromyelitis Optica Revenue by Countries (2015-2020) (USD Million)
Table 108. Middle East & Africa Drugs for Neuromyelitis Optica Revenue Market Share by Countries (2015-2020)
Table 109. Global Drugs for Neuromyelitis Optica Sales by Type (2015-2020) (K Units)
Table 110. Global Drugs for Neuromyelitis Optica Sales Share by Type (2015-2020)
Table 111. Global Drugs for Neuromyelitis Optica Revenue by Type (2015-2020) (USD Million)
Table 112. Global Drugs for Neuromyelitis Optica Revenue Share by Type (2015-2020)
Table 113. Global Drugs for Neuromyelitis Optica Sales by Application (2015-2020) (K Units)
Table 114. Global Drugs for Neuromyelitis Optica Sales Share by Application (2015-2020)
Table 115. Global Drugs for Neuromyelitis Optica Sales Forecast by Regions (2021-2025) (K Units)
Table 116. Global Drugs for Neuromyelitis Optica Market Share Forecast by Regions (2021-2025)
Table 117. Global Drugs for Neuromyelitis Optica Sales Forecast by Type (2021-2025) (K Units)
Table 118. Global Drugs for Neuromyelitis Optica Market Share Forecast by Type (2021-2025)
Table 119. Global Drugs for Neuromyelitis Optica Sales Forecast by Application (2021-2025)
Table 120. Global Drugs for Neuromyelitis Optica Market Share Forecast by Application (2021-2025)
Table 121. Direct Channel Pros & Cons
Table 122. Indirect Channel Pros & Cons
Table 123. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Drugs for Neuromyelitis Optica Picture
Figure 2. Global Sales Market Share of Drugs for Neuromyelitis Optica by Type in 2019
Figure 3. Glucocorticoids Picture
Figure 4. Immunotherapies Picture
Figure 5. Other Picture
Figure 6. Drugs for Neuromyelitis Optica Sales Market Share by Application in 2018
Figure 7. Acute Attack Picture
Figure 8. Remission Prophylactic Treatment Picture
Figure 9. Global Drugs for Neuromyelitis Optica Market Status and Outlook (2015-2025) (USD Million)
Figure 10. United States Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 11. Canada Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Mexico Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Germany Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 14. France Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 15. UK Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Russia Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Italy Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 18. China Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Japan Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Korea Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 21. India Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Southeast Asia Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Australia Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 24. Brazil Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Egypt Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Saudi Arabia Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 27. South Africa Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Turkey Drugs for Neuromyelitis Optica Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Global Drugs for Neuromyelitis Optica Sales Market Share by Manufacturer in 2019
Figure 30. Global Drugs for Neuromyelitis Optica Revenue Market Share by Manufacturer in 2019
Figure 31. Top 3 Drugs for Neuromyelitis Optica Manufacturer (Revenue) Market Share in 2019
Figure 32. Top 6 Drugs for Neuromyelitis Optica Manufacturer (Revenue) Market Share in 2019
Figure 33. Key Manufacturer Market Share Trend
Figure 34. Global Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 35. Global Drugs for Neuromyelitis Optica Revenue and Growth Rate (2015-2020) (USD Million)
Figure 36. Global Drugs for Neuromyelitis Optica Revenue Market Share by Regions (2015-2020)
Figure 37. Global Drugs for Neuromyelitis Optica Revenue Market Share by Regions in 2018
Figure 38. North America Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
Figure 39. Europe Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
Figure 41. South America Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
Figure 42. Middle East & Africa Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020)
Figure 43. North America Drugs for Neuromyelitis Optica Revenue and Growth Rate (2015-2020) (USD Million)
Figure 44. North America Drugs for Neuromyelitis Optica Sales Market Share by Countries (2015-2020)
Figure 45. North America Drugs for Neuromyelitis Optica Sales Market Share by Countries in 2018
Figure 46. North America Drugs for Neuromyelitis Optica Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 47. North America Drugs for Neuromyelitis Optica Revenue Market Share by Countries in 2018
Figure 48. United States Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 49. Canada Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 50. Mexico Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 51. Europe Drugs for Neuromyelitis Optica Revenue and Growth Rate (2015-2020) (USD Million)
Figure 52. Europe Drugs for Neuromyelitis Optica Revenue Market Share by Countries (2015-2020)
Figure 53. Europe Drugs for Neuromyelitis Optica Revenue Market Share by Countries in 2019
Figure 54. Germany Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 55. UK Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 56. France Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 57. Russia Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 58. Italy Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 59. Asia-Pacific Drugs for Neuromyelitis Optica Revenue and Growth Rate (2015-2020) (USD Million)
Figure 60. Asia-Pacific Drugs for Neuromyelitis Optica Sales Market Share by Regions 2019
Figure 61. Asia-Pacific Drugs for Neuromyelitis Optica Revenue Market Share by Regions 2019
Figure 62. China Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 63. Japan Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 64. Korea Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 65. India Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 66. Southeast Asia Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 67. South America Drugs for Neuromyelitis Optica Revenue and Growth Rate (2015-2020) (USD Million)
Figure 68. South America Drugs for Neuromyelitis Optica Sales Market Share by Countries in 2019
Figure 69. South America Drugs for Neuromyelitis Optica Revenue Market Share by Countries in 2019
Figure 70. Brazil Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 71. Argentina Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 72. Middle East and Africa Drugs for Neuromyelitis Optica Revenue and Growth Rate (2015-2020) (USD Million)
Figure 73. Middle East and Africa Drugs for Neuromyelitis Optica Sales Market Share by Countries in 2019
Figure 74. Middle East and Africa Drugs for Neuromyelitis Optica Revenue Market Share by Countries (2015-2020)
Figure 75. Middle East and Africa Drugs for Neuromyelitis Optica Revenue Market Share by Countries in 2019
Figure 76. Saudi Arabia Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 77. Egypt Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 78. Turkey Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 79. South Africa Drugs for Neuromyelitis Optica Sales and Growth Rate (2015-2020) (K Units)
Figure 80. Global Drugs for Neuromyelitis Optica Sales and Growth Rate (2021-2025) (K Units)
Figure 81. Global Drugs for Neuromyelitis Optica Revenue and Growth Rate (2021-2025) (USD Million)
Figure 82. North America Sales Drugs for Neuromyelitis Optica Market Forecast (2021-2025) (K Units)
Figure 83. Europe Sales Drugs for Neuromyelitis Optica Market Forecast (2021-2025) (K Units)
Figure 84. Asia-Pacific Sales Drugs for Neuromyelitis Optica Market Forecast (2021-2025) (K Units)
Figure 85. South America Sales Drugs for Neuromyelitis Optica Market Forecast (2021-2025) (K Units)
Figure 86. Middle East & Africa Sales Drugs for Neuromyelitis Optica Market Forecast (2021-2025) (K Units)
Figure 87. Sales Channel: Direct Channel vs Indirect Channel
脊髄炎視神経スペクトラム障害治療薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The Neuromyelitis Optic Spectrum Disorder Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, val…- 血漿由来薬物の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Plasma Derived Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Plasma Derived Drugs mar…
- 幹細胞薬品の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Stem Cell Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Stem Cell Drugs market report…
- アンチエイジング薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Anti-Ageing Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 7.2% in the forecast period of 2020 to 2025 and will expected to reach USD 106360 million by 2025, from USD 80490 million in 2019. The Anti-Ageing Drugs m…
- 乾癬性関節炎治療薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Psoriatic Arthritis Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Psoriatic Arthritis…